Allergy & Intolerance

From HL7Wiki
Jump to navigation Jump to search

Return to: Patient Care


Allergy/Intolerance Project Meeting Minutes

Allergy/Intolerance Project Conference Calls and Meeting Minutes



Allergy/Intolerance and Adverse Reaction Projects

The Allergy/Intolerance and Adverse Reaction topic comprises a number of phases:

  • Allergy and Intolerance Substance Value Set(s)Definition Informative Document
  • Allergy/Intolerance Domain Analysis phase, which aimed at producing a Domain Analysis Model (DAM)
  • Allergy/Intolerance and Adverse Reaction clinical model development phase, which aims at producing of a set of HL7 clinical models DSTU to support exchanges of allergy/intolerance and adverse reaction information
  • Implementation guide - project scope yet to be defined
  • Harmonization of Allergy and Intolerance concepts in V3, C-CDA R1.1, C-CDA R2.0 and FHIR


Food substance sub-project

Food Substances Sub Group Project

Drug substance sub-project

Allergy & Intolerance Drug Sub-project

Document for ballot

Leadership (project co-leads)

Elaine Ayres

Russ Leftwich

Stephen Chu


Allergy/Intolerance Topic Scope Statements



Current work: Create an Allergy and Intolerance Domain Analysis Model and Clinical Models (DSTU).

Project 881 (Domain Analysis Model) and Project 1004 (Clinical Models) This is a work in progress. See HL7 Ballot site for existing specification.

This topic covers all interactions related to clinically recorded adverse reactions, including:

  • Recording adverse reactions
  • Revising existing adverse reaction records
  • Retrieving a patient's adverse reaction records

These transactions are not intended for reporting adverse reactions (as managed by Individual Case Safety Reports). Rather, these transactions are intended to be recorded as part of a patient's electronic health record. They supplement allergy and intolerance records for circumstances where it is not clear whether an allergy or intolerance exists. These interactions are crafted to support a 'request-based' architecture in which messages are sent from a point of service (POS) such as a clinic, pharmacy, etc. to a central drug information system (DIS). These messages are phrased as requests because the DIS reserves the right to refuse all requests. Reasons might include the presence of contraindications such as drug-drug interactions or duplicate therapy, as well as more mundane issues such as lack of permission, lack of recorded patient consent, etc.


Allergy/Intolerance Topic DSTU

The current "Allergy/Intolerance" topic DSTU expires in June 2012. The "Allergy/Intolerance" project group after some discussion recommends that application to HL7 publishing committee for a 12-month extension of the current DSTU should be considered as the best option forward. The 12-month extension will allow the group with time to perform proper DAM development and to determine how best the current DSTU may be modified and/or extended to meet updated, new requirements.

The following is DSTU extension guidance provided by HL7 HQ:

DSTU extension guidance is offered at the TSC wiki page under TSC Process Guidance, at: http://hl7t3f.org/wiki/index.php?title=DSTU_Publishing_Guidance, where requesting extensions to DSTU should use criteria determined in the TSC’s conference call 2009-03-09:

“Sufficient justification should be provided to describe effort in progress to move the standard towards a normative ballot, such as evidence of current trial activity, if they have a credible expectation that a normative document will be produced within a requested timeframe, given that trials are currently underway. The request must include the length of time required to extend the DSTU, including conclusion of the pilot and subsequent balloting activity...If you send the completed form to me (LynnL) I can put it on the TSC agenda.”



Domain Analysis Model (DAM)

Allergy/Intolerance DAM project is completed.

This is the artefact produced by the project:

Ballot reconciliation is complete for this DAM as of May 8, 2013. Final Domain Analysis Model will be published with changes.


To help with harmonization with FHIR resources, a recent (2014-10-30) discussion thread regarding Adverse Event v Adverse Reaction (to substance) v Propensity to Adverse Reaction (to substance) has emerged.

Ballot Reconciliation January 2013


Harmonization Activities and Related Materials



Allergy/Intolerance and Adverse Reaction Projects: Document Collection

The Allergy/Intolerance and Adverse Reaction projects produced a number of artefacts which can be accessed through the following links:


C-CDA Terminology Analysis for DAM and C-CDA r1.1 Harmonization Project:Terminology Analysis - Elaine Ayres June 2014

Presentations


2012 Use Cases and Storyboards


2013 Use Cases and Storyboards



Updated Allergy and Intolerance Glossary


Past Use Cases and Storyboards



Models



Links to Other Relevant Projects

Structured Document WG: CDA Implementation Guilde Project on Clinical Oncology Treatment Plan and Summary:

http://wiki.hl7.org/index.php?title=Clinical_Oncology_Treatment_Plan_and_Summary



Discussions

Current discussion on topic